(ATTAC-II) A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Patients with Newly-Diagnosed Glioblastoma


The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.

Study details

Dendritic cells (DC) are involved in activating, or turning-on, your body's immune system. Your immune system helps guard your body from germs, viruses, and other threats. Although dendritic cells are very strong, the number of them in the body is not high enough to cause a powerful immune response; therefore, more DC are made in a laboratory with cells collected from an individual's blood.

In this study, we will make a vaccine that we hope will educate immune cells to target the pp65 antigen, a type of immune marker in GBM, thus resulting in what we call the pp65 DC vaccine. Use of a vaccine that activates your immune system is a type of immunotherapy. It is hoped that by giving the pp65 DC vaccine as a shot under the skin, the immune system will be activated to attack tumor cells in the brain while leaving normal cells alone.

To see if the pp65 DC vaccine is effective for the treatment of GBM, subjects will be assigned to different treatment groups. Two groups of subjects will receive the pp65 DC vaccine and one group will receive a placebo.


Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.


  • Ages 18 years old and older
  • Histopathologically proven newly-diagnosed de novo GBM (secondary GBM not eligible).
  • CMV seropositive.
  • The tumor must have a supratentorial component
  • Must have undergone definitive surgical resection of tumor with less than 1cm x 1cm residual enhancing tumor in longest perpendicular planes by MRI.
  • Recovery from the effects of surgery, postoperative infection, and other complications.
  • Diagnostic contrast-enhanced MRI or CT scan of the brain preoperatively and postoperatively.
  • Karnofsky Performance Status of ≥ 70.
  • Signed informed consent.
  • For females of childbearing potential, negative serum pregnancy test.
  • Women of childbearing potential and male participants must be willing to practice adequate contraception.


For additional study details and eligibility, please contact Hoai Deleyrolle:


18 to 65
65 and over




Glioma, Recurrent Glioblastoma, Glioblastoma multiforme

Principal Investigator

Maryam Rahman, M.D.

Sponsoring Group

Department of Neurosurgery


Department of Neurosurgery

Contact Information



Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams